Gene-modified T cells (GM T cells) | Norton Healthcare

Indication: Gene-modified T cells (GM T cells)

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Chimeric Antigen Receptor (CAR) T cells

Line of Therapy: Long Term Follow up for Subjects Treated with Gene-Modified T Cells

Specimen

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Celgene

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.